ACHV News and Press, Achieve Life Sciences Inc. From 04/25/23

2023-04-25 16:37:49 ET Summary Positive Phase 2 ORCA-V1 trial results show cytisinicline's potential in helping users quit vaping, with an odds ratio of 2.6 compared to placebo, suggesting a strong case for FDA approval. Cytisinicline demonstrated a favorable safety profile with n...

2023-04-20 10:04:03 ET Gainers: Augmedix ( AUGX ) +67% . CNS Pharmaceuticals ( CNSP ) +65% . Petros Pharmaceuticals ( PTPI ) +36% . ContraFect ( CFRX ) +20% . Dermata Therapeutics ( DRMA ) +14% . Losers: Windtree Therapeut...

2023-04-20 09:29:27 ET Canadian biotech Achieve Life Sciences ( NASDAQ: ACHV ) added ~5% pre-market Thursday after announcing data from a Phase 2 trial to indicate that those who received cytisinicline, its experimental therapy for nicotine addiction, were more than two times li...

First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of Cytisinicline for Treatment of Nicotine Dependence Management to Host Conference Call Today...

SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced tha...

SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announ...

SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announ...

2023-03-16 21:33:05 ET Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Conference Call March 16, 2023 16:30 ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer ...

2023-03-16 16:18:35 ET Achieve Life Sciences press release ( NASDAQ: ACHV ): Q4 GAAP EPS of -$0.83 beats by $0.06 . As of December 31, 2022, the company’s cash, cash equivalents, and restricted cash was $24.8 million. Total operating expenses for the f...

SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, tod...